Elacytarabine (BioDeep_00000837788)
Cytotoxicity
代谢物信息卡片
化学式: C27H45N3O6 (507.330819)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCCCCCC/C=C/CCCCCCCC(OC[C@H]([C@@H](O)[C@@H]1O)O[C@H]1N2C(N=C(N)C=C2)=O)=O
InChI: InChI=1S/C27H45N3O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(31)35-20-21-24(32)25(33)26(36-21)30-19-18-22(28)29-27(30)34/h9-10,18-19,21,24-26,32-33H,2-8,11-17,20H2,1H3,(H2,28,29,34)/b10-9+/t21-,24-,25+,26-/m1/s1
描述信息
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite
Elacytarabine (CP 4055) is a lipid-conjugated derivative of the nucleoside analog cytarabine. Elacytarabine (CP 4055) is an antineoplastic agent with cytotoxicity in solid tumors.
同义名列表
2 个代谢物同义名
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:177700
- KEGGdrug: D09712
- PubChem: 6438895
- DrugBank: DB05494
- ChEMBL: CHEMBL2105665
- CAS: 101235-34-1
- CAS: 188181-42-2
- medchemexpress: HY-14941
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Steven Knapper, Timothy Chevassut, Rafael Duarte, Juan Miguel Bergua, Olga Salamero, Malin Johansen, Tove Flem Jacobsen, Petter-Arnt Hals, Wenche Rasch, Athos Gianella-Borradori, Matthew Smith. Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile.
Leukemia research.
2014 Mar; 38(3):346-51. doi:
10.1016/j.leukres.2013.12.011. [PMID: 24433865] - Courtney D DiNardo, Susan O'Brien, Varsha V Gandhi, Farhad Ravandi. Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.
Future oncology (London, England).
2013 Aug; 9(8):1073-82. doi:
10.2217/fon.13.130. [PMID: 23902239] - Niamh Keane, Ciara Freeman, Ronan Swords, Francis J Giles. Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.
Expert review of hematology.
2013 Feb; 6(1):9-24. doi:
10.1586/ehm.12.68. [PMID: 23373775] - Susan O'Brien, David A Rizzieri, Norbert Vey, Farhad Ravandi, Utz O Krug, Mikkael A Sekeres, Mike Dennis, Adriano Venditti, Donald A Berry, Tove Flem Jacobsen, Karin Staudacher, Trygve Bergeland, Francis J Giles. Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia.
British journal of haematology.
2012 Sep; 158(5):581-8. doi:
10.1111/j.1365-2141.2012.09186.x. [PMID: 22702906] - Aine Carol Burke, Frank James Giles. Elacytarabine--lipid vector technology overcoming drug resistance in acute myeloid leukemia.
Expert opinion on investigational drugs.
2011 Dec; 20(12):1707-15. doi:
10.1517/13543784.2011.625009. [PMID: 22040175] - Svein Dueland, Steinar Aamdal, Michael J Lind, Hilary Thomas, Marit Liland Sandvold, Jean-Michel Gaullier, Wenche Rasch. Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study.
Acta oncologica (Stockholm, Sweden).
2009; 48(1):137-45. doi:
10.1080/02841860802183620. [PMID: 18607882] - W Rubas, A Supersaxo, H G Weder, H R Hartmann, H Hengartner, H Schott, R Schwendener. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
International journal of cancer.
1986 Jan; 37(1):149-54. doi:
10.1002/ijc.2910370123. [PMID: 3941019]